Evidence map›Paper›PMID 37470885›Full record

ArticleAAPS PharmSciTech2023

Exploring Penetration Ability of Carbonic Anhydrase Inhibitor-Loaded Ultradeformable Bilosome for Effective Ocular Application.

Vishnumaya S Nair, Vaibhavi Srivastava, Valamla Bhavana, Rati Yadav, Naveen Rajana, Shashi Bala Singh, Neelesh Kumar Mehra

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vishnumaya S Nair *Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India.
Vaibhavi Srivastava *Pharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India.
Valamla BhavanaPharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India.
Rati YadavPharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India.
Naveen RajanaPharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India.
Shashi Bala SinghDepartment of Biological Science, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India.
Neelesh Kumar MehraPharmaceutical Nanotechnology Research Laboratory, Department of Pharmaceutics, Ministry of Chemical and Family Welfare, National Institute of Pharmaceutical Education and Research (NIPER), Telangana, 500 037, Hyderabad, India. neelesh@niperhyd.ac.in.ORCID http://orcid.org/0000-0001-5275-8065

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brinzolamide is an effective carbonic anhydrase inhibitor widely used in glaucoma therapy but limits its application due to inadequate aqueous solubility and permeability. The aim of the present research work is the development and characterization of brinzolamide-loaded ultradeformable bilosomes to enhance the corneal permeation of the drug. These ultradeformable bilosomes were prepared by ethanol injection method and evaluated for physicochemical properties, particle size, morphology, drug release, ultra-deformability, corneal permeation, and irritation potential. The optimized formulation exhibited an average particle size of 205.4 ± 2.04 nm with mono-dispersity (0.109 ± 0.002) and showed entrapment efficiency of 75.02 ± 0.017%, deformability index of 3.91, and release the drug in a sustained manner. The brinzolamide-loaded ultradeformable bilosomes released 76.29 ± 3.77% of the drug in 10 h that is 2.25 times higher than the free drug solution. The bilosomes were found non-irritant to eyes with a potential irritancy score of 0 in Hen's egg-chorioallantoic membrane assay. Brinzolamide-loaded ultradeformable bilosomes showed 83.09 ± 5.1% of permeation in 6 h and trans-corneal permeability of 8.78 ± 0.14 cm/h during the ex vivo permeation study. The acquired findings clearly revealed that the brinzolamide-loaded ultradeformable bilosomes show promising output and are useful in glaucoma therapy.

Indexed as

Carbonic Anhydrase InhibitorsGlaucomaAnimalsChickensCorneaFemaleParticle SizeSulfonamidesThiazinesbrinzolamideCarbonic Anhydrase InhibitorsSulfonamidesThiazinesbile saltsbrinzolamidecarbonic anhydrase inhibitorchorioallantoic membranecornea permeationHET-CAMultradeformable bilosomes

Identifiers

PMID37470885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.